A Non-interventional Trial of Erlotinib (Tarceva) Metastatic Non-small Cell Lung Cancer
Launched by HOFFMANN-LA ROCHE · Nov 2, 2015
Trial Information
Current as of April 25, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • It is the physician's decision to prescribe erlotinib in participants and to document their treatment
- • Participants must be candidates for receiving erlotinib for locally advanced or metastatic non-small cell lung cancer according to the product label
- Exclusion Criteria:
- • Participants will be excluded if safety concerns occurred
- • If the participant was not compliant or if the participant would wish to stop erlotinib therapy
Trial Officials
Clinical Trials
Study Director
Hoffmann-La Roche
About Hoffmann La Roche
Hoffmann-La Roche, commonly known as Roche, is a global leader in biotechnology and pharmaceuticals, committed to advancing healthcare through innovative research and development. With a strong focus on oncology, immunology, infectious diseases, and central nervous system disorders, Roche leverages cutting-edge science to deliver transformative therapies and diagnostics. The company is dedicated to improving patient outcomes by conducting rigorous clinical trials and collaborating with healthcare professionals and organizations worldwide. Roche's unwavering commitment to precision medicine and personalized healthcare positions it at the forefront of the industry, driving progress in the quest for effective treatments and improved patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bludesch, , Austria
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials
Related Blog Entries
View all
